Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.
Stanford researchers have developed high-titer bacteriophage and annexin V formulations for rapid, more effective phage therapy against bacterial infection.
Researchers at Stanford and their colleagues have developed new antibiotic compounds that could be used to treat staph infection (caused by Staphylococcus aureus) and TB infection (caused by Mycobacterium tuberculosis).